Abstract:The inflammation is the protective response of the body against various harmful stimuli; however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines [IL-1β, IL-2, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)], growth factor, and chemokines. These mediators make the inflammatory microenvironment more vulnerable toward tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as nuclear factor kappa B, MAPKinase, nuclear factor erythroid 2-related factor 2, phosphoinositide-3-kinase, Janus kinases/STAT, Wnt/B-catenin, and cyclic AMP response element binding protein. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, natural killer cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending on the type of tumor and immune cells involved. Tumor-associated macrophages and tumor-associated neutrophils are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. By contrast, cytotoxic T cells and T helper cells confer antitumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and antitumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer composed of tumor-infiltrating lymphocytes has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.

The Cross-Talk of Non-coding RNAs and Inflammation in Human Cancer.

Crosstalk between Environmental Inflammatory Stimuli and Non-Coding RNA in Cancer Occurrence and Development

Noncoding RNAs Link Metabolic Reprogramming to Immune Microenvironment in Cancers

The Role of Non-Coding RNA in Tumorigenesis, Development,diagnosis and Treatment

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk

Noncoding RNAs: Regulating the Crosstalk Between Tumor-Associated Macrophages and Gastrointestinal Cancer

Long non-coding RNAs and cancer mechanisms: Immune cells and inflammatory cytokines in the tumor microenvironment

Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs

The Role of NcRNAs to Regulate Immune Checkpoints in Cancer

Involvement of Non-coding RNAs in the Signaling Pathways of Colorectal Cancer

Noncoding RNAs: New Players in Cancers.

[MicroRNAs and nonresolving inflammation-related cancer].

Crosstalk Between the Notch Signaling Pathway and Non-Coding RNAs in Gastrointestinal Cancers.

Non-Coding RNAs and Innate Immune Responses in Cancer

Non-Coding RNAs: Key Regulators of CDK and Wnt/β-catenin signaling in Cancer

Long Non-Coding RNAs, Nuclear Receptors and Their Cross-Talks in Cancer—Implications and Perspectives

Non-coding RNAs: the New Central Dogma of Cancer Biology

The crosstalk between non-coding RNAs and oxidative stress in cancer progression

Emerging Roles of Noncoding RNAs in Human Cancers

Long Non-Coding RNA and Non-Coding Nucleic Acids: Signaling Players in the Networks of the Tumor Ecosystem